Status:
ACTIVE_NOT_RECRUITING
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Lead Sponsor:
Bayer
Collaborating Sponsors:
Biogen Netherlands B.V
Novartis Europharm Limited
Conditions:
Multiple Sclerosis (MS)
Eligibility:
FEMALE
12-64 years
Brief Summary
Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the ...
Eligibility Criteria
Inclusion
- Women with a diagnosis of MS disease, regardless of MS clinical type, recorded at least once during the full study period.
- Women with at least one recorded pregnancy after the MS diagnosis (including pregnancies ending in live birth, stillbirth, spontaneous abortion, ectopic pregnancy, or elective termination)
Exclusion
- \- None.
Key Trial Info
Start Date :
March 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2026
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT06053749
Start Date
March 20 2024
End Date
March 31 2026
Last Update
December 26 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Multiple Locations, Finland
2
Many locations
Multiple Locations, Sweden